Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

While there are no studies documenting the number of physicians taking GLP-1s, a number of physicians told the Times that they've noticed many colleagues growing thinner and sharing similar eating ...

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded ...

Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss drugs, but the jury's out on w ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 41 tables and 85 figures, this 159-page report ?Asia Pacific Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

Oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering improved patient comfort and ...